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Abstract
Identification of unintended drug effects, specifically drug repurposing opportunities and
adverse drug events, maximizes the benefit of a drug and protects the health of patients.
However, current observational research methods are subject to several biases. These
include confounding by indication, reverse causality and missing data. We propose that
Mendelian randomization (MR) offers a novel approach for the prediction of unintended
drug effects. In particular, we advocate the synthesis of evidence from this method and
other approaches, in the spirit of triangulation, to improve causal inferences concerning
drug effects. MR addresses some of the limitations associated with the existing methods
in this field. Furthermore, it can be applied either before or after approval of the drug,
and could therefore prevent the potentially harmful exposure of patients in clinical trials
and beyond. The potential of MR as a pharmacovigilance and drug repurposing tool is
yet to be realized, and could both help prevent adverse drug events and identify novel in-
dications for existing drugs in the future.
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Key Messages
• We propose that the prediction of unintended drug effects using MR can overcome some of the limitations associated
with existing methods, including confounding by indication, reverse causality and missing data.
• We demonstrate the potential of MR for predicting unintended drug effects using examples from the literature of
studies that have assessed recognized unintended drug effects.
• We advocate the synthesis of evidence from MR and other approaches, in the spirit of triangulation, to improve
causal inferences concerning drug effects.
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Introduction
Adverse drug events and drug repurposing opportunities
are both unintended drug effects. Drug repurposing,
defined as the application of known drugs to new indica-
tions, offers a time- and cost-effective alternative to trad-
itional drug development.1 Adverse drug events, defined as
any unwanted reaction to a drug, risk patient safety and in-
crease the burden on health care systems.2 The opportuni-
ties offered by drug repurposing and the potential harm
caused by adverse drug events means the identification of
unintended drug effects is necessary to maximize the bene-
fit of a drug and protect health.
Unintended effects of drugs can be discovered through-
out the drug development process. However, before ap-
proval of a novel drug, its risk-benefit profile cannot be
fully known. This is because pre-approval clinical trials are
principally for demonstrating the drug’s efficacy for its in-
tended indication. This limits the trial’s ability to assess
safety and identify novel indications in a number of ways.3
First, the comparatively small number of patients exposed
to a drug during a pre-approval clinical trial means that
only very common or very large drug effects can be de-
tected. Second, the length of time that patients are exposed
to the drug in this setting is relatively short. Third, the re-
corded data may not include the necessary information to
identify previously unknown drug effects or those that are
unrelated to the drug’s indication. Finally, the participants
of a study may not represent the broad range of patients
seen in clinical practice. As a result of this, continued as-
sessment of drugs after approval is necessary in order to
fully develop their profile.
After approval of a drug, unintended drug effects can be
identified in several ways. Adverse drug events are primar-
ily identified through the use of spontaneous reporting sys-
tems, which rely on health care professionals and members
of the public to report suspected drug effects.4–6 Drug
repurposing opportunities are often sought directly by
pharmaceutical companies using purpose-built drug repur-
posing technology platforms, due to their desirable risk-
versus-reward trade-off.7 Strong signals from these data-
bases and technology platforms are then investigated using
data from a range of sources, including: randomized clin-
ical trials (RCTs) either before or after approval of the
drug; meta-analyses of such trials; observational studies;
and information from basic science.3 However these meth-
ods, particularly spontaneous reporting systems, suffer
from several biases including their inability to determine
causality, over-reporting from media coverage, confound-
ing by indication and other usually unobserved confound-
ers. Minimizing these biases is therefore key to
determining which of these signals indicate a true unin-
tended drug effect.
Mendelian Randomization
We propose that Mendelian randomization (MR) offers a
novel approach for the prediction of unintended drug effects,
which overcomes some of the limitations associated with
existing methods.8–10 In particular, we advocate the synthesis
of evidence from MR with that from other sources, in the
spirit of triangulation, to improve causal inferences of drug
effects.11 MR assesses the causal effect of an exposure on an
outcome by using a genetic variant as a proxy for exposure.
For example, MR can interrogate the unintended drug effects
associated with statins. Statins inhibit the enzyme 3-
hydroxy-3-methylglutaryl-CoA reductase (HMGCR) to
lower low-density lipoprotein (LDL) cholesterol and conse-
quently reduce the risk of coronary heart disease (CHD). An
MR study would use one or a combination of single nucleo-
tide polymorphisms (SNPs) located in the vicinity of the
HMGCR gene as a proxy for exposure to statins. The prin-
ciple behind this is that randomization occurs naturally at
conception, when genetic variants are allocated at random to
individuals from their parents. The genetic variants allocated
at germ cell formation and conception are part of the germ-
line genome–this is represented in studies by the data col-
lected from routine genotyping. Post-zygotic alterations to
the germline can occur in the somatic genome, with such al-
terations contributing to the development of many cancers
and some other diseases. Using germline genetic variants for
the prediction of unintended drug effects has a number of
strengths and limitations associated with it, which are dis-
cussed in detail later.12 MR can therefore be thought of as
analogous to an RCT that uses genetic variation as the
method of randomization, as demonstrated in Figure 1. The
key distinction is that MR can be done using routine geno-
typing data, without the exposure of patients to the drug.
Potential unintended drug effects include: drug
substance specific effects; mechanism effects; and bio-
marker effects. These effects are best presented in terms of
the statin example discussed previously. Drug substance
specific effects are effects that relate only to the particular
drug compound received–this means different compounds
within a class of drugs produce different effects. For ex-
ample, it has been suggested that there is an increased risk
of fatal rhabdomyolysis associated with cerivastatin com-
pared with other statins, and this has led to it being with-
drawn from the market.13–17 Mechanism effects are effects
resulting from changes to a specific enzyme or biological
pathway but not changes resulting from the biomarker. In
terms of statins, this would be changes resulting from the
inhibition of HMGCR and not those resulting from
changes in LDL cholesterol.18–20 For example, multiple
statins may have lipid-independent effects resulting from
HMGCR inhibition. These effects include improvement of
endothelial function, though there is limited direct
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evidence for this in humans at present.20–22 Finally, bio-
marker effects are the effects that result from changes in
the biomarker, i.e. changes in LDL cholesterol level, which
occur regardless of the mechanism used to induce that
change. For example, reduced LDL cholesterol appears to
increase the risk of type 2 diabetes independent of the
mechanism of LDL reduction.23–26 This has been demon-
strated by Ference et al., who found that for three mechan-
isms–HMGCR, proprotein convertase subtilisin/kexin type
9 (PCSK9) and low-density lipoprotein receptor (LDLR)–
‘each set of gene-specific variants . . . had a very similar
effect as the other sets on the risk of diabetes per unit de-
crease in the LDL cholesterol level’.27 Understanding the
difference between effects is key to understanding what is
possible with MR in this context.
Examples
The potential of MR for predicting unintended drug effects
in the future is highlighted by studies that have assessed
recognized unintended drug effects. We will consider two
examples: one for the prediction of adverse drug events
and the other for the prediction of drug repurposing oppor-
tunities. In the case of the former, consider once more the
example of statins prescribed for the prevention of CHD.
Statins increase the risk of new-onset type 2 diabetes—a
risk that is recognized by both the Medicines and Health
Care Products Regulatory Agency (MHRA) in the UK and
the Food and Drug Administration (FDA) in the USA.28,29
This risk was originally assessed using evidence from a
meta-analysis of randomized statin trials.25 Since the
recognition of this adverse drug event, Swerdlow et al. con-
ducted an MR study to assess whether the increase in new-
onset type 2 diabetes risk is a result of the inhibition of
HMGCR, i.e. the enzyme targeted by statins. To do this,
they used the SNP rs17238484 as a proxy because it is
located on the HMGCR gene and has been associated with
lower LDL cholesterol in a large genome-wide study of lip-
ids.24,30 Swerdlow et al. found ‘each additional
rs17238484-G allele was associated with a mean
006 mmol/l [95% confidence interval (CI) 0.05–0.07]
lower LDL cholesterol and higher body weight (030 kg,
0.18–0.43), waist circumference (0.32 cm, 0.16–0.47),
plasma insulin concentration (1.62%, 0.53–2.72) and
plasma glucose concentration (0.23%, 0.02–0.44)’.23 This
led them to conclude that inhibition of HMGCR ‘at least
partially’ explains the increased risk of type 2 diabetes. In
principle, MR could potentially have provided evidence of
this effect before licensing and before the exposure of large
numbers of patients. In this case, MR could also have pre-
dicted the balance of benefits and risks of statin treatment
in terms of CHD reduction and type 2 diabetes increase
Random assignment
MR: allocaon of SNP on the HMGCR gene at concepon
RCT: allocaon to stan treatment or no stan treatment
Exposed
MR: individuals with SNP on the 
HMGCR gene corresponding to 
high inhibion
RCT: individuals receiving stan 
treatment
Control
MR: individuals with SNP on the 
HMGCR gene corresponding to low 
inhibion
RCT: individuals receiving no stan 
treatment
Outcomes compared between groups
MR: comparison of individuals with SNP on the HMGCR gene corresponding 
to high inhibion versus individuals with SNP on the HMGCR gene 
corresponding to low inhibion
RCT: comparison of individuals receiving stan treatment versus individuals 
receiving no stan treatment
Figure 1. The process by which MR mimics the action of a drug. This diagram shows how MR can be thought of as analogous to an RCT. To predict
unintended effects of a drug, the mechanism that the drug alters must be identified so that a suitable proxy for the drug can be identified. Naturally,
this mechanism will differ between individuals because of genetic variation. MR therefore uses the random allocation of genetic variants to mimic al-
location (or not) to the drug of interest.
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(which generally show an overall markedly predictable
effect).16
The second example focuses on the potential of MR for
predicting drug repurposing opportunities. It is thought to
take around 10 years from the point where a drug is first
tested in humans to the point where it is a licensed treat-
ment.7,31,32 This means we are yet to see the full benefit of
the results from large-scale genome-wide association stud-
ies (GWAS) being made available for drug development.
Nonetheless, there are several recent examples that high-
light the future possibilities. For example, consider serum
calcium and the risk of migraine. A study by Yin et al. re-
cently investigated this relationship by implementing three
methods, including an MR analysis using a genetic score
that explained 1.25% of variation in serum calcium levels.
Based on this score they found ‘an elevation of serum cal-
cium levels by a hypothetical 1 mg/dl . . . . was associated
with an increase in risk of migraine [odds ratio (OR) 1.80,
95% CI 1.31–2.46, P¼ 2.4 x 104]’, which was supported
by their other two methods.33 The paper then went on to
highlight several therapeutic options that may be possible
based on this evidence. These included the use of the drug
Cinacalcet, which is already approved by the FDA, to an-
tagonize the calcium-sensing receptor (CaSR). This drug
was suggested based on the variant rs1801725, which is in
the CASR gene and associated with both serum calcium
levels and increased migraine susceptibility. The authors
advised caution due to hypocalcaemia risk, but indicated
that Cinacalcet may be a drug repurposing opportunity
worth investigating in ‘specific instances’. Another poten-
tial therapeutic option arising from this study related to
the use of calcium channel blockers (CCBs). Although
existing evidence is mixed for the use of these drugs for mi-
graine, the authors suggested that the vasodilatory effects
of CCBs accompanied by direct manipulation of Ca2þ lev-
els could be beneficial based on their findings.
Further opportunities to predict unintended drug effects
are detailed in Table 1. Recent work by Finan et al., to esti-
mate the druggable genome, termed 144 licensed drug targets
as having a ‘discordant disease association and target indica-
tion considered to imply a potential repurposing opportun-
ity’. A further 27 licensed drug targets were termed as having
a ‘disease association corresponding to a mechanism-based
adverse effect’.34 This work, which used an MR approach for
the study of drug effects across the whole genome, along with
the selected examples presented in Table 1, illustrate the im-
mense opportunity provided by this method.
Existing Genetic Methods
The use of genetics for pharmacovigilance and drug repur-
posing has previously been discussed; however, the
potential of MR for this purpose is yet to be fully real-
ized.35,36 Until now the discussion has focused on the use
of genome- and phenome-wide association studies (GWAS
and PheWAS, respectively).37–40 GWAS search for the gen-
etic variants associated with a given phenotype, and
PheWAS search for phenotypes associated with a given
genetic variant. In these studies, the genetic variant will be
a proxy for the exposure and the phenotype will be an un-
intended drug effect. MR extends the use of genetics for
pharmacovigilance and drug repurposing, as it can either
be used on a single outcome, or combined with a ‘pheno-
type screen’ for the prediction of effects of drugs on a wide
range of outcomes. The concept of MR with phenotype
screening was first introduced by Millard et al., who pro-
posed MR-PheWAS. MR-PheWAS uses ‘automated screen-
ing with genotypic instruments to screen for causal
associations amongst any number of phenotypic outcomes’.41
This approach is hypothesis-free and could therefore be of
great use for generating hypotheses concerning potential un-
intended drug effects, particularly before approval of a drug.
Limited phenotypic screening with MR has previously
been demonstrated in the literature by the Interleukin 1
Genetics Consortium in their investigation of the long-
term effects of interleukin 1 (IL-1) inhibition.42 This study
used a GWAS in order to inform the construction of a gen-
etic score. The score combined the information for two
SNPs, rs6743376 and rs11687782, which were upstream
of the 1L1RN gene and had been shown in the GWAS to
be independently associated with circulating IL-1 receptor
antagonist concentration.43 The study concluded that
‘human genetic data suggest that long-term dual IL-1a/b
inhibition could increase cardiovascular risk and, con-
versely, reduce the risk of development of rheumatoid arth-
ritis’.42 Note that the results of this study do not
necessarily extend to inhibition of IL-1b alone–an RCT of
which recently found a reduced risk of cardiovascular
events.44 Since this study, the development of databases of
harmonized summary GWAS results, such as MR-Base
[http://www.mrbase.org/], has made the implementation of
MR in this way much simpler.45 The use of MR therefore
has immense potential for the prediction of adverse drug
events and drug repurposing opportunities, with or with-
out a priori hypotheses. Furthermore, MR and the related
genetic methods can be used with non-genetic approaches
in order to better explore the relationship between the gen-
ome and phenome.46 Bush et al. discuss how genetic data
can be linked with data from electronic health records and
epidemiological studies in order to better characterize ‘the
impact of one or more genetic variants on the phenome’ in
the PheWAS setting.47 An MR-PheWAS that implemented
such an approach could be a particularly powerful tool for
the prediction of unintended drug effects.
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Table 1. Opportunities to predict unintended drug effects using MR with potential genetic variants identified from the GTEx
eQTL Catalog74 using MR-Base45
Drug Potential proxy
genetic variant(s)
Mechanism Biomarker Target disease
Aldehyde dehydro-
genase inhibitors
rs201649047 Acetaldehyde
dehydrogenase
Acetaldehyde Alcohol
dependencers11066055
rs592967
rs11608345
rs111900779
rs7963329
rs57186456
rs201574057
rs847892
rs200037659
rs11066018
Angiotensin-convert-
ing enzyme
inhibitors
rs4311 Angiotensin-convert-
ing enzyme
Blood pressure Hypertension
rs6504163
rs4277405
rs4330
Carbonic anhydrase
II inhibitors
rs11329721 Carbonic anhydrase
II
Intraocular
pressure
Open-angle
glaucomars10090196
rs3839863
rs13282987
rs62512073
rs79597773
Cholesteryl ester
transfer protein
inhibitors
rs821840 Cholesteryl ester
transfer protein
Low-density
lipoprotein
cholesterol
Coronary heart
diseasers11508026
rs201940645
Ezetimibe rs411279633 Niemann-pick C1-
like 1
Low-density
lipoprotein
cholesterol
Coronary heart
diseasers199683176
rs217402
rs11972520
rs745833
Fatty acid amide
hydrolase
inhibitors
rs7520850 Fatty acid amide
hydrolase
Anandamide Inflammatory
chronic painrs6429600
rs2145409
rs7555240
rs2145409
rs2145409
rs6429600
rs56083025
rs35361357
rs56083025
rs6429600
rs7555240
rs4660346
rs2145409
rs56083025
rs11804189
rs12217016
rs201127808
Gonadotrophin-
releasing hormone
antagonists
rs28526365 Gonadotropin-
releasing hormone
receptors
Luteinising
hormone
Prostate cancer
rs12651577
rs145250522
rs17634475
(continued)
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Strengths and Limitations
MR has a number of strengths and limitations associated
with its use, which are summarized in Table 2. In the fol-
lowing sections, we will highlight some of the strengths
that make MR particularly suited to the prediction of unin-
tended drug effects, as well as the limitations that it may be
susceptible to in this context.
Strengths
Addresses confounding by indication
Confounding by indication occurs in observational studies
when the factors predisposing a patient to receive treat-
ment are also the factors related to an increased risk of
experiencing an outcome.48 This can induce an artificial
association between the drug exposure and an observed
outcome. MR minimizes confounding by indication be-
cause the genetic variant used to proxy drug exposure is
unlikely to be affected by the indications for such drug ex-
posure. Let us continue with the example of statins pre-
scribed for the prevention of CHD: existing cardiovascular
disease is a major indication for taking statins. At the same
time, patients with cardiovascular disease are also at
increased risk of death. This can induce an observational
association between statin use and increased risk of cardio-
vascular death. But this association is not caused by statins,
it is due to the indication: risk of cardiovascular disease.49
MR reduces confounding by indication as the SNP located
on the HMGCR gene, used to proxy exposure to statins, is
a germline variant and so is unlikely to be a result of the in-
dication, i.e. cardiovascular disease.
Table 1. Continued
Drug Potential proxy
genetic variant(s)
Mechanism Biomarker Target disease
rs12651577
rs141552662
rs147425774
rs398107462
rs145250522
rs11283415
rs199604647
rs147425774
rs1484186
rs71219068
rs13124793
rs11282189
Proprotein conver-
tase subtilisin/
kexin type 9
inhibitors
rs2495503 Proprotein conver-
tase subtilisin/
kexin type 9
Low-density
lipoprotein
cholesterol
Coronary heart
diseasers34232196
rs479910
Selenium rs673752 Dimethylglycine
dehydrogenase
Plasma selenium Prostate cancer
rs28326
rs7714738
rs7356546
rs146701923
rs72764983
rs248381
rs485851
rs6453427
rs684277
rs1717567
rs1274984
rs7719892
Statins rs17244897 3-hydroxy-3-methyl-
glutaryl-coenzyme
A reductase
Low-density
lipoprotein
cholesterol
Coronary heart
disease
Several of these drugs have already been the subject of MR studies, including ezetimibe and statins.23,27,61 However, these drugs could still benefit from further
research, particularly combining MR with a ‘phenotype screen’ (MR-PheWAS) in order to generate hypotheses.41
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More robust to non-genetic confounding and reverse
causation
MR uses germline genetic variants that are less likely to be
confounded by environmental, lifestyle or disease-related
factors operating later in life.50–52 Consequently, if a gen-
etic variant is associated with an outcome only through its
association with a drug effect, it is likely to be because the
genetic variant causes the outcome.53 Thus, MR should
provide robust evidence about the causal effects of inter-
vening on specific biological pathways. This is particularly
important when considering physiological factors that
change over the life course, such as LDL cholesterol and es-
trogen levels, because the association of such factors with
the outcome is likely to be heavily confounded by environ-
ment and lifestyle factors, as well as potentially being sub-
ject to reverse causation. For example, epidemiological
studies have previously suggested that hormone replace-
ment therapy (HRT) could be protective against CHD.
Results from these studies are summarized in a meta-
analysis by Stampfer et al., which found the relative risk to
be 0.56 (95% CI 0.50–0.61).54 However, these results are
contrary to a number of clinical trials.55 Lawlor et al. sug-
gest that a possible explanation for this contradiction is the
effect of early life socioeconomic position. They found ‘ad-
verse socioeconomic factors from across the life course
were associated with use of HRT’, in a study using data
from the British Women’s Heart and Health Study.56 An
MR study, which should not be subject to bias caused by
socioeconomic position at any point in the life course, has
since been conducted using data from young women in
Hong Kong and older women in the Guangzhou Biobank
Cohort Study. Unlike the observational studies, the MR
analysis was in line with the results of the clinical trials and
concluded that ‘genetically higher 17 b-estradiol was not
associated with any cardiovascular disease-related risk fac-
tor or with Framingham score (0.01, 95% confidence
interval¼1.34 to 1.31).’57 This MR analysis therefore
confirms that HRT is unlikely to be a suitable drug-
repurposing candidate for CHD, without concerns about
bias due to socioeconomic position.
Can be used either before or after approval of a drug
MR does not require the exposure of patients to the drug–
this means it can be implemented at any point during the
drug development process and beyond. This can: increase
the efficiency of drug development by identifying unsuit-
able targets; allow pre-specification of likely adverse out-
comes in trials; and reduce the possibility of exposing
patients to unnecessary risks and harm. For example, con-
sider the potential use of selenium dietary supplements for
the prevention of prostate cancer. The Selenium and
Vitamin E Cancer Prevention Trial (SELECT) found that
selenium did not lower prostate cancer risk but did in-
crease the risk of type 2 diabetes. An MR study, conducted
after the trial, found that genetically elevated selenium was
not associated with prostate cancer risk and was positively
associated with type 2 diabetes risk (Martin RM, personal
communication).58 Implementation of MR before the trial
could therefore have been an informative step in the assess-
ment of selenium as a possible chemoprevention target.
Able to predict combined effects of drugs
Many medicines are only licensed for use when other treat-
ments are either being used concurrently or have been pre-
viously used and failed. This makes the assessment of the
‘additive’ effect of drugs increasingly important. For ex-
ample, the results of the Further Cardiovascular Outcomes
Research with PCSK9 Inhibition in Subjects with Elevated
Risk (FOURIER) trial, for the PCSK9 inhibitor evolocu-
mab to reduce LDL cholesterol, have recently been pub-
lished.59 This trial was conducted against a background of
taking statins. Before this and other PCSK9 inhibitor trials,
Table 2. Strengths and limitations associated with MR
Strengths • Addresses confounding by indication
• More robust to non-genetic confounding
• More robust to reverse causation
• Can be used either before or after approval of a
drug
• Able to predict combined effects of drugs
• Aids the distinction of mechanism and biomarker
effects
• Addresses missing data
• Limits associative selection biasa
• Minimizes regression dilution biasa
Limitations • Rare effects may not be detected
• Choice of genetic variant can lead to missed ef-
fects or conflicting resultsa,b
• Horizontal pleiotropy
• Estimates are of lifelong exposure
• Lack of genetic variants concerning disease
progression
• Unintended drug effects must have large genetic
association studies available
• Genomic confounding
• Weak instrument biasa
• Linkage disequilibrium (non-independence of gen-
etic variants)a
• Combining genetic variants within a model can
confound resultsa
aThese strengths and limitations are not discussed in detail here, but further
information can be found in the referenced literature. 9,12,50,73
bWe discuss in detail how the choice of genetic variant can lead to missed
effects; however, it may also lead to conflicting results. This can happen if the
chosen genetic variant alters the relationship between the exposure and the
biomarker or affects multiple biomarkers related to a single disease.
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there had been concerns that PCSK9 inhibitors may have
similar effects in terms of type 2 diabetes risk as statins.
This led to several MR studies being conducted, including
an analysis by Ference et al. that examined this risk using
variation in PCSK9, HMGCR or both.27 The MR study
found PCSK9 variants to have a similar effect as HMGCR
variants on the risk of cardiovascular events (OR 0.81,
0.74–0.89 vs OR 0.81, 0.72–0.90) and the risk of type 2
diabetes (OR 1.11, 1.04–1.19 vs 1.13, 1.06–1.20) for each
10 mg per dl decrease in LDL cholesterol level. The trial
found that the lipid-lowering effect of the PCSK9 inhibitor
evolocumab was in line with statins and ‘the rates of adju-
dicated cases of new-onset diabetes did not differ signifi-
cantly between the two groups (hazard ratio, 1.05; 95%
CI, 0.94 to 1.17)’.59 In addition, both the trial and the MR
analysis were in agreement that the lipid-lowering effect of
statins and PCSK9 inhibitors is additive. Given these over-
lapping results, further trial data are required to assess the
risk of type 2 diabetes associated with the use of PCSK9 in-
hibitors. However, the consistency of the MR results and
the trial clearly demonstrates the value of MR analyses
and, in particular, the ability to consider the combined ef-
fects of drugs before patient exposure.
Aids the distinction of mechanism and biomarker effects
MR is able to distinguish mechanism and biomarker effects
by enabling a formal statistical comparison of the effect
of a biomarker influenced by different drug-related
The potenal unintended drug 
eﬀect is observed as a result of 
one of the mechanisms studied 
but not the other - this is 
suggesve of a mechanism 
eﬀect.
e.g. The potenal unintended 
drug eﬀect is observed for the 
SNPs on the PCSK9 gene but not 
the HMGCR gene, suggesng 
that it is a mechanism eﬀect of 
PCSK9 (or vice versa).
Perform MR of the biomarker on the potenal unintended drug eﬀect for 
the mechanism of interest and an alternave mechanism.
e.g. Perform MR of LDL cholesterol on the potenal unintended drug 
eﬀect using SNPs on the PCSK9 gene and repeat using SNPs on the 
HMGCR gene.
Is the eﬀect of the biomarker on the potenal unintended drug eﬀect the 
same regardless of the mechanism used?
e.g. Is the eﬀect of LDL cholesterol indicated by SNPs on the PCSK9 gene 
and the HMGCR gene the same?
The potenal unintended drug 
eﬀect is observed regardless of 
the mechanism that alters the 
biomarker - this is suggesve of 
a biomarker eﬀect.
e.g. The potenal unintended 
drug eﬀect is observed for both 
the SNPs on the PCSK9 and the 
HMGCR genes, suggesng that it 
is a biomarker eﬀect of LDL 
cholesterol.
Compare the eﬀect of the biomarker indicated by the mechanism of 
interest versus the eﬀect indicated by the alternave mechanism.
e.g. Compare the eﬀect of LDL cholesterol indicated by SNPs on the 
PCSK9 gene versus the eﬀect indicated by SNPs on the HMGCR gene.
No Yes
Figure 2. The process by which MR can be used to distinguish mechanism and biomarker effects of drugs. This diagram shows that if a potential un-
intended drug effect is indicated by the SNPs on multiple genes, then it is suggestive of a biomarker effect. This is because the effect occurs regard-
less of the mechanism used to induce the change. If this is not the case, the unintended drug effect is suggestive of a mechanism effect relating to the
SNPs that indicated it. This is because the effect is specific to just one mechanism that induces a change in the biomarker, and not all possible
mechanisms.
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mechanisms to be made.20,60,61 This process is illustrated
in Figure 2. Unfortunately, genetic variants that proxy spe-
cific drug substances are rare, and so it is difficult to distin-
guish drug substance specific effects from the other effect
types. MR suggests that an effect is mechanistic if genetic
variants for a biomarker mediated by one mechanism af-
fect a downstream phenotype, but variants that are medi-
ated via an alternative mechanism do not. If all variants for
a biomarker affect the downstream phenotype regardless
of the mechanism, then this suggests a biomarker effect.
For example, Ference et al. suggested that the cause of
increased type 2 diabetes risk may be related to an LDL
receptor-mediated pathway, i.e. may be a biomarker effect,
based on the study described earlier. This was due to the
similarity of the variant effects for HMGCR, the mechan-
ism of statins, and those for PCSK9, the mechanism of
PCSK9 inhibitors–along with specific assessment of poten-
tial shared pathways.27 Other genetic studies have found
similar results.26,27,62
Addresses missing data
The use of genetic variants to proxy an exposure in MR
can address missing or incomplete exposure, outcome or
confounder data. GWAS are increasingly publishing the as-
sociations between all genetic variants and their outcome.
This means that the associations between a genetic variant
and an outcome can be looked up in databases of GWAS
results, such as MR Base [http://www.mrbase.org/], and
the need for new analysis of individual-level data is
removed.45 Provided there are robust genetic variants for
the drug exposure of interest (see Table 1 for examples)
and there are large genetic association studies of the out-
come, MR should not be limited by missing or incomplete
data.
Limitations
Genomic confounding
MR can be subject to genomic confounding, which occurs
when the causality of a genetic variant is misinterpreted.
An example of this is population stratification. Genetic
variants occur at different frequencies in different popula-
tions. This means if, for instance, different ethnicities have
different rates of outcomes, differences due to ethnicity
could be incorrectly ascribed to the risk factor of interest.
Rare effects may not be detected
Single-sample MR studies, where the instrument-
therapeutic target associations and the instrument-
unintended drug effect associations are recorded in the
same dataset, are not suited to detecting rare unintended
drug effects. This is due to the power and data availability
issues associated with such effects. For example, it has
been suggested that rhabdomyolysis may be a mechanism
effect of statins that is more pronounced for cerivastatin,
rather than a drug-specific effect of cerivastatin. The global
incidence of rhabdomyolysis is unknown but it is thought
to be rare, with an estimated 26 000 cases per year occur-
ring in the USA according to the 1995 National Hospital
Discharge Survey.64,65 This means that single-sample MR
studies are unlikely to have sufficient power to detect
rhabdomyolysis as a mechanism effect of statins.66–69
Two-sample MR studies, which use results from large
GWAS for the instrument-therapeutic target associations
and case-control GWAS for the instrument-unintended
drug effect associations, may be the best approach to over-
come this limitation. Note that rhabdomyolysis is a sus-
pected rare unintended drug effect. Investigation of
previously unknown rare unintended drug effects would
require a hypothesis-free approach. Although this is theor-
etically possible, it will be hard to achieve with the cur-
rently available resources. Curation of a database of
GWAS for classical rare unintended drugs effects that
drugs could be tested against, in an MR framework, would
make such investigations more feasible.
Choice of genetic variant can lead to missed effects
Unintended drug effects may be missed if you chose a gen-
etic variant to proxy exposure downstream of the effect
you are interested in. For example, if you chose a genetic
variant at the biomarker level (i.e. related to LDL choles-
terol level) to investigate statins, then the mechanism ef-
fects (i.e. the lipid-independent effects such as improved
endothelial function) may be missed. In addition to this,
genetic association studies often investigate only common
genetic variants or combine the effect of rare genetic vari-
ants. This results in a situation where individual genetic
variants may explain very little of the observed variation.
Careful consideration must therefore be given to the choice
of genetic variant when conducting an MR study.
Horizontal pleiotropy
Horizontal pleiotropy, where a genetic variant influences
multiple phenotypes through distinct pathways, is a par-
ticular concern for MR analyses.10 This can occur if you
choose a genetic variant that relates to multiple biomarkers
on different pathways, which could affect the outcome of
interest. This is because the MR estimate will be biased by
the effect of the variant on biomarkers other than the bio-
marker of interest. Some methods are potentially more ro-
bust to certain types of pleiotropy, such as the weighted
median and MR-Egger regression methods: these methods
are discussed in detail elsewhere.70,71
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Estimates are of lifelong exposure
MR estimates indicate lifelong perturbations in an expos-
ure. Therefore, careful consideration of the exposure and
its timing must be made to avoid misinterpretation of re-
sults.12,72 For example, some exposures are cumulative
whereby repeated exposure, over a sustained period, re-
sults in the outcome. MR analyses of such exposures are
likely to overestimate the effect observed in other study de-
signs, including RCTs, as these designs consider much
shorter periods of exposure with lower compliance. A further
example is time-dependent exposures. MR analyses of this
type of exposure can provide misleading evidence about the
effect of manipulating an exposure after the critical period.
This is because the MR estimate will, by definition, include
any critical periods in its assessment of lifelong exposure.
Lack of genetic variants concerning disease progression
A large proportion of the genetic variants that have been
identified to date are concerned with the incidence of dis-
ease. In order to predict unintended drug effects that relate
to the treatment of that disease, genetic variants relating to
progression will need to be identified. Paternoster et al. re-
cently commented that ‘Only a small proportion of GWAS
studies [8% of associations curated in the GWAS
Catalog (P< 1 x 105)] have attempted to identify variants
associated with disease progression or severity and those
that have are mostly small (90% have n< 5000)’.73 This
limits the treatments we can study at present using MR;
however, this can be rectified with increased focus on large
GWAS concerning disease progression in the future.
Conclusion
MR offers a novel and appealing approach for the predic-
tion of unintended drug effects, which can address some of
the limitations associated with existing methods in this
field. In addition, MR can provide additional benefits,
such as use before approval of a drug, and be used in tri-
angulation with evidence from other methods to improve
causal inferences concerning unintended drug effects. The
potential of MR as a pharmacovigilance and drug repur-
posing tool is yet to be realized. Future use of this method
in the development of drug profiles could both help pre-
vent adverse drug events and identify novel indications for
existing drugs.
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